STING1 and graft versus host disease: In summary, we have shown that correctly timed therapeutic activation of RIG-I or STING may offer a strategy to reduce gut epithelial barrier dysfunction and promote epithelial integrity during acute tissue damage caused by chemotherapy or TBI and thus help to prevent the development of GVHD.